Skip to main content

EcoR1 Reports a $5.3 Million ZYME Purchase

January 3, 2025

Today’s most notable transaction comes via a Form 4 filing by EcoR1 Capital LLC, a biotech-focused hedge fund known for its expertise in high-growth life sciences investments.

The fund revealed a purchase of 363,369 shares of Zymeworks Inc $ZYME, equivalent to $5,321,175. EcoR1’s ownership stake in ZYME is now 22.04%.

Here’s The Hot Corner, with data from January 2, 2024:

But it doesn't end there. EcoR1 Capital also stepped in for a purchase of AnaptysBio $ANAB shares with a total value of $1,099,642. ANAB is now the largest holding in EcoR1’s portfolio.

Article Sales Message

Know the trading behavior of …

  • Senators
  • House Of Representatives
  • C-Suite Executives
  • Hedge Fund Managers
  • Other Big-Power Players

Our experienced team of analysts work through the Form 4, 13D and 13G filings to provide you a list of the best trade ideas.

You need to have a subscription to access this content in full.

Log in or subscribe
Filed Under: